Global Information, Inc.
日商環球訊息有限公司
網站導覽
產業/市場分類
有興趣參與全球國際會議(展示會)嗎?
英文調查報告書

歐洲的藥品開發生物晶片市場

Biochips in Drug Discovery in Europe

出版商 Frost & Sullivan 聯絡我們
出版日期 2005/06 內容資訊
商品編碼 32679
價格 US $ 6,950 ~ Price List
US $ 6,950 Web Access (Regional License)
US $ 7,450 Hard Copy & Web Access (Regional License)
本頁所標示之售價為不含購買者所在地消費稅之未稅價格,相關消費稅金將另行加至交易金額中
aaaaaaa
PDF by E-Mail
2個工作天後到貨
Hard Copy/CD-ROM
約5個工作天左右
TOC
此出版品為英文撰寫

Research Overview

Biochip Technology takes Drug Discovery to New Heights

Biochip technology has revolutionised and added a new dimension to the field of drug discovery. Biochips employed in tandem, with improved bioinformatics techniques and high throughput screening has enabled a dramatic increase in sample throughput in target identification and target validation. They offer higher information content on a small surface of quartz wafers. Increasingly, larger volumes of compounds are being pushed through the drug discovery pipeline. This has created a vast consumer base for biochips in Europe including academic research units, industrial research bases and pharma and biotech companies.

This Frost & Sullivan research service analyses the potential that biochips hold to accelerate the drug discovery pathway at the European strata. The study segments the market by application into deoxyribonucleic acid (DNA) chips and protein chips and by geographical region into Germany, France, Italy, the United Kingdom, Switzerland, Benelux (Belgium, the Netherlands and Luxembourg) and Scandinavia (Sweden, Finland, Denmark, Iceland, Norway). The study also discusses the various trends and opportunities in each country while providing in-depth market share analysis, forecasts, drivers, restraints and revenue forecasts.

Multi-parameter Testing and Miniaturisation of Chip Technology Offer Promises of Reducing Drug Development Time

Miniaturisation and high throughput solutions have realised and added value to gene expression analysis, which can speed drug discovery by dramatically cutting down the attrition rate of drugs that do not pass clinical trials. Biochips have streamlined the identification and prioritization of the drug targets by corroborating many gene expressions in parallel. "With the aid of silicon micro-machining, lab automation devices and robust software packages to churn out data in a meaningful format, these developments are expected to advance the proliferation of biochips to unprecedented heights in drug discovery.", says the analyst of this research service.

Expression profiling with the use of biochips helps identify drug targets and pathways for complex disease mechanisms. To evaluate a drug target during drug design, the disease pathway of the particular drug is chosen before genome expression profiling influences different possible genes and analyses the effects on the pathway. After selective identification and validation of drug targets, the biochips are used to screen the collection of compounds to identify those targets that disrupt the expression of diseased genes.

Strategic Alliances Nurture the Growth of Biochip Use in Drug Discovery Process

Despite the intense rivalry in the biochip-driven drug discovery market, companies are forming a web of strong alliances intended at bringing together business expertise and key intellectual properties. Established chip companies are collaborating with firms that own great biocontent to increase their penetration rate. Smaller firms are gaining visibility and continuing to be competent in the dynamic market by affiliating themselves with the larger, well-recognised suppliers through licensing and distributorships. Strategic alliances between chip companies and pharmaceutical firms also represent a major factor generating growth in the market.

"Companies are striving to provide open platform technologies to attract all end users, especially the academic research base that forms a major part of the biochip community," says the analyst. The best approach for providing better value propositions includes understanding customers requirements and managing the technical aspects, budget issues, strategic regulatory issues and quality assurance related to the products. Although biochips have empowered researchers with the most innovative technology, only cost-effective solutions can make them a part of the routine product development process.

@

1 EXECUTIVE SUMMARY

Executive Summary
Industry Snapshot

2 GLOSSARY AND EXCHANGE RATES

Exchange Rates & Glossary
Glossary of Terms
Exchange Rate

3 TOTAL MARKET-BIOCHIPS

Biochip Market Overview
Market Overview and Definition
Segmentation
Market Segmentation
Market Engineering Measurements for Biochips Market -Drug Discovery Applications
Market Engineering Measurements
Biochip Market Drivers
Market Drivers
Biochip Market Restraints/Challenges
Market Restraints/Challenges
Total European Biochip Revenue Forecasts
Revenue Forecasts
Geographical Trends
Geographical Trends for the European Biochips Market
German Biochips Market
United Kingdom Biochips Market
French Biochips Market
Technology Trends
Technology Trends
Competitive Structure
Competitive Landscape
End-user Trends and Analysis
End-user Trends

4 DNA CHIPS

Introduction
Introduction and Market Overview
Market Engineering Measurements
Market Engineering Measurements for the DNA Chip segment
Market Revenue Forecasts
Revenue Forecasts
Competitive Landscape in the DNA Chip sector
Competition Structure

5 PROTEIN CHIPS

Introduction and Market Overview
Introduction
Market Engineering Measurements
Market Engineering Measurements for the European Protein Chip Market
Market Revenue Forecasts
Revenue Forecasts
Competitive Landscape in the Protein Chip Sector
Competitive Landscape - Protein Chips

6 FROST & SULLIVAN AWARDS

Frost & Sullivan Awards for the European Biochips Market
Frost & Sullivan Award Description
Product Line Strategy Award
Award Description
Competitive Strategy Leadership Award
Award Description
Entrepreneurial Company Award
Award Description

7 STRATEGIC RECOMMENDATIONS

Strategic Recommendations
Possible Strategies

8 DSD FOR BIOCHIPS IN DRUG DISCOVERY APPLICATIONS

Biotech Companies and Number of Employess
Biotech Companies
Number of Employees in Biotech Companies
Government R&D Expenditure
Government R&D Expenditure
Private Investment in Biotechnology
Private Investment in Biotechnology
Pharmaceutical R&D Expenditure
Pharmaceutical R&D expenditure

9 DATABASE OF KEY INDUSTRY PARTICIPANTS (DKIP)

Database of key Industry Participants
Database of Industry Participants

相關報告
Top